Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53-mutant mantle cell lymphoma
Br J Haematol
.
2025 Jun 23.
doi: 10.1111/bjh.20202.
Online ahead of print.
Authors
Manik Uppal
1
,
Ashlee Joseph
2
,
Esther Drill
3
,
Paul Hamlin
2
4
,
Lorenzo Falchi
2
4
,
Ariela Noy
2
4
,
Colette Owens
2
4
,
Zachary D Epstein-Peterson
2
4
,
Gilles Salles
2
4
,
Andrew D Zelenetz
2
4
,
Anita Kumar
2
4
Affiliations
1
Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
2
Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
3
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
4
Department of Medicine, Weill Cornell Medical College, Cornell University, New York, New York, USA.
PMID:
40551465
DOI:
10.1111/bjh.20202
No abstract available
Keywords:
P53; lymphomas; molecular analysis; mutations.